1
|
Depreter F, Pilcer G, Amighi K. Inhaled proteins: Challenges and perspectives. Int J Pharm 2013; 447:251-80. [DOI: 10.1016/j.ijpharm.2013.02.031] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2013] [Accepted: 02/12/2013] [Indexed: 12/26/2022]
|
2
|
Manunta MDI, McAnulty RJ, Tagalakis AD, Bottoms SE, Campbell F, Hailes HC, Tabor AB, Laurent GJ, O'Callaghan C, Hart SL. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium. PLoS One 2011; 6:e26768. [PMID: 22046351 PMCID: PMC3202583 DOI: 10.1371/journal.pone.0026768] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2011] [Accepted: 10/04/2011] [Indexed: 11/19/2022] Open
Abstract
Background Gene therapy mediated by synthetic vectors may provide opportunities for new treatments for cystic fibrosis (CF) via aerosolisation. Vectors for CF must transfect the airway epithelium efficiently and not cause inflammation so they are suitable for repeated dosing. The inhaled aerosol should be deposited in the airways since the cystic fibrosis transmembrane conductance regulator gene (CFTR) is expressed predominantly in the epithelium of the submucosal glands and in the surface airway epithelium. The aim of this project was to develop an optimised aerosol delivery approach applicable to treatment of CF lung disease by gene therapy. Methodology The vector suspension investigated in this study comprises receptor-targeting peptides, cationic liposomes and plasmid DNA that self-assemble by electrostatic interactions to form a receptor-targeted nanocomplex (RTN) of approximately 150 nm with a cationic surface charge of +50 mV. The aerodynamic properties of aerosolised nanocomplexes produced with three different nebulisers were compared by determining aerosol deposition in the different stages of a Next Generation Pharmaceutical Impactor (NGI). We also investigated the yield of intact plasmid DNA by agarose gel electrophoresis and densitometry, and transfection efficacies in vitro and in vivo. Results RTNs nebulised with the AeroEclipse II BAN were the most effective, compared to other nebulisers tested, for gene delivery both in vitro and in vivo. The biophysical properties of the nanocomplexes were unchanged after nebulisation while the deposition of RTNs suggested a range of aerosol aerodynamic sizes between 5.5 µm–1.4 µm cut off (NGI stages 3–6) compatible with deposition in the central and lower airways. Conclusions RTNs showed their ability at delivering genes via nebulisation, thus suggesting their potential applications for therapeutic interventions of cystic fibrosis and other respiratory disorders.
Collapse
Affiliation(s)
- Maria D. I. Manunta
- Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, University College London, London, United Kingdom
| | - Robin J. McAnulty
- Centre for Respiratory Research, University College London, London, United Kingdom
| | - Aristides D. Tagalakis
- Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, University College London, London, United Kingdom
| | - Stephen E. Bottoms
- Centre for Respiratory Research, University College London, London, United Kingdom
| | - Frederick Campbell
- Department of Chemistry, University College London, London, United Kingdom
| | - Helen C. Hailes
- Department of Chemistry, University College London, London, United Kingdom
| | - Alethea B. Tabor
- Department of Chemistry, University College London, London, United Kingdom
| | - Geoffrey J. Laurent
- Centre for Respiratory Research, University College London, London, United Kingdom
| | - Christopher O'Callaghan
- Department of Infection, Immunity and Inflammation, University of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom
| | - Stephen L. Hart
- Wolfson Centre for Gene Therapy of Childhood Disease, UCL Institute of Child Health, University College London, London, United Kingdom
- * E-mail:
| |
Collapse
|
3
|
Mével M, Yaouanc JJ, Laurent P, Clément JC, Cartier D, Jaffrès PA, Montier T, Delépine P, Le Gall T, Lehn P, Pichon C, Midoux P, Férec C. Cationic Lipids Based on Phosphonate and Phosphoramidate Chemistry: Synthesis and Application to Gene Therapy. PHOSPHORUS SULFUR 2008. [DOI: 10.1080/10426500701761300] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Mathieu Mével
- a CEMCA, UMR CNRS 6521, Faculté des Sciences et Techniques , Université de Bretagne Occidentale , Brest, France
| | - Jean-Jacques Yaouanc
- a CEMCA, UMR CNRS 6521, Faculté des Sciences et Techniques , Université de Bretagne Occidentale , Brest, France
| | - Pascale Laurent
- a CEMCA, UMR CNRS 6521, Faculté des Sciences et Techniques , Université de Bretagne Occidentale , Brest, France
| | - Jean-Claude Clément
- a CEMCA, UMR CNRS 6521, Faculté des Sciences et Techniques , Université de Bretagne Occidentale , Brest, France
| | - Dominique Cartier
- a CEMCA, UMR CNRS 6521, Faculté des Sciences et Techniques , Université de Bretagne Occidentale , Brest, France
| | - Paul-Alain Jaffrès
- a CEMCA, UMR CNRS 6521, Faculté des Sciences et Techniques , Université de Bretagne Occidentale , Brest, France
| | - Tristan Montier
- b Unité INSERM 613 “Génétique Moléculaire et Epidémiologie Génétique”, Institut de Synergie des Sciences et de la Santé, Faculté de médecine et des sciences de la santé , Université de Bretagne Occidentale , Brest, France
| | - Pascal Delépine
- b Unité INSERM 613 “Génétique Moléculaire et Epidémiologie Génétique”, Institut de Synergie des Sciences et de la Santé, Faculté de médecine et des sciences de la santé , Université de Bretagne Occidentale , Brest, France
| | - Tony Le Gall
- b Unité INSERM 613 “Génétique Moléculaire et Epidémiologie Génétique”, Institut de Synergie des Sciences et de la Santé, Faculté de médecine et des sciences de la santé , Université de Bretagne Occidentale , Brest, France
| | - Pierre Lehn
- b Unité INSERM 613 “Génétique Moléculaire et Epidémiologie Génétique”, Institut de Synergie des Sciences et de la Santé, Faculté de médecine et des sciences de la santé , Université de Bretagne Occidentale , Brest, France
| | | | | | - Claude Férec
- c Centre de Biophysique Moléculaire , Orléans, France
| |
Collapse
|
4
|
Courtête J, Sibler AP, Zeder-Lutz G, Dalkara D, Oulad-Abdelghani M, Zuber G, Weiss E. Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-oncoprotein E6 antibody and small interfering RNA. Mol Cancer Ther 2007; 6:1728-35. [PMID: 17575104 DOI: 10.1158/1535-7163.mct-06-0808] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cervical cancer is caused by high-risk types of human papillomaviruses (HPV) that encode the E6 and E7 oncogenes. Silencing of E6 gene expression in HPV-positive cell lines by transfection of small interfering RNA (siRNA) with cationic lipids restores the dormant p53 tumor suppressor pathway. Because cationic lipids can also be used for intracytoplasmic delivery of proteins, we tested whether the delivery of monoclonal antibodies that bind to HPV16 E6 and neutralize its biological activity in vitro could restore p53 function in tumor cells. Here, we show that the 4C6 antibody is efficiently delivered into the cell cytoplasm using a lipidic reagent used for siRNA transfection. The delivery of 4C6 resulted in the nuclear accumulation of p53 protein in CaSki and SiHa cells but not in HeLa cells. Furthermore, the antibody-mediated p53 response was dramatically increased when a peptide corresponding to the 4C6 epitope and bearing a COOH-terminal cysteine residue was added to the transduction mixture. We found that a fraction of the added peptides were dimers that allowed the formation of antibody polymers adsorbed onto the lipidic matrix. With this system, the proliferation of CaSki and SiHa cells was strongly diminished, but no apoptosis was detectable. Remarkably, cell growth was almost totally suppressed by the addition of E6-specific siRNA to the transduction complex. The results indicate that the activity of E6 oncoprotein can be down-regulated in vivo by lipid-mediated antibody delivery and that antibodies and siRNA act synergistically when codelivered. This novel targeting strategy is simple to implement and may find therapeutic applications.
Collapse
Affiliation(s)
- Jérôme Courtête
- Institut Gilbert-Laustriat, UMR 7175, ESBS, Illkirch Cedex, France
| | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
Cationic lipids are conceptually and methodologically simple tools to deliver nucleic acids into the cells. Strategies based on cationic lipids are viable alternatives to viral vectors and are becoming increasingly popular owing to their minimal toxicity. The first-generation cationic lipids were built around the quaternary nitrogen primarily for binding and condensing DNA. A large number of lipids with variations in the hydrophobic and hydrophilic region were generated with excellent transfection efficiencies in vitro. These cationic lipids had reduced efficiencies when tested for gene delivery in vivo. Efforts in the last decade delineated the cell biological basis of the cationic lipid gene delivery to a significant detail. The application of techniques such as small angle X-ray spectroscopy (SAXS) and fluorescence microscopy, helped in linking the physical properties of lipid:DNA complex (lipoplex) with its intracellular fate. This biological knowledge has been incorporated in the design of the second-generation cationic lipids. Lipid-peptide conjugates (peptoids) are effective strategies to overcome the various cellular barriers along with the lipoplex formulations methodologies. In this context, cationic lipid-mediated gene delivery is considerably benefited by the methodologies of liposome-mediated drug delivery. Lipid mediated gene delivery has an intrinsic advantage of being a biomimetic platform on which considerable variations could be built to develop efficient in vivo gene delivery protocols.
Collapse
Affiliation(s)
- N Madhusudhana Rao
- Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad, 500 007, India.
| | | |
Collapse
|
6
|
Koumbi D, Clement JC, Sideratou Z, Yaouanc JJ, Loukopoulos D, Kollia P. Factors mediating lipofection potency of a series of cationic phosphonolipids in human cell lines. Biochim Biophys Acta Gen Subj 2006; 1760:1151-9. [PMID: 16730412 DOI: 10.1016/j.bbagen.2006.03.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2005] [Revised: 03/04/2006] [Accepted: 03/07/2006] [Indexed: 10/24/2022]
Abstract
A series of cationic liposomes known as cationic phosphonolipids (CPs) were evaluated as vehicles for in vitro gene transfer in K562 erythroleukemia cells and 5637 epithelial carcinoma cells. For each CP and target cell type examined, detailed analyses were performed to determine optimal transfection conditions (lipid/ DNA (+/-) charge ratio, amount of complexed episomal DNA, liposomal and lipoplex size, complexation medium and duration of complex-cell exposure time). Lipofection conditions were determined to be both cell- and lipid-type specific. Complexation medium critically affected transfection competence. The initial size of the liposome was not always predictive of lipofection potency. The lipid chemical composition had a strong impact upon lipofection efficiency; DOPE inclusion in the liposome formulations was found to affect the levels of transgene expression in a cell-dependent way. Notably, effective transgene expression was characterized by prominent plasmid nuclear incorporation. Human A gamma- and epsilon-globin transgene nuclear incorporation and expression in 5637 cells post GLB.391-mediated lipofection lends credence to its use as a vehicle of therapeutic transgene delivery.
Collapse
Affiliation(s)
- Daphne Koumbi
- First Department of Medicine, University of Athens, School of Medicine, Athens, Greece
| | | | | | | | | | | |
Collapse
|
7
|
Abstract
Extensive research efforts have been directed towards the systemic administration of therapeutic proteins and poorly absorbed macromolecules via various nontraditional, injection-free administration sites such as the lung. As a portal for noninvasive delivery, pulmonary administration possesses several attractive features including a large surface area for drug absorption. Nevertheless, achieving substantial bioavailability of proteins and macromolecules by this route has remained a challenge, chiefly due to poor absorption across the epithelium. The lungs are relatively impermeable to most drugs when formulated without an absorption enhancer/promoter. In an attempt to circumvent this problem, many novel absorption promoters have been tested for enhancing the systemic availability of drugs from the lungs. Various protease inhibitors, surfactants, lipids, polymers and agents from other classes have been tested for their efficacy in improving the systemic availability of protein and macromolecular drugs after pulmonary administration. The purpose of this article is to provide the reader with a summary of recent advances made in the field of pulmonary protein delivery utilizing absorption enhancers. This report reviews the various agents used to increase the bioavailability of these drugs from the lungs, their mechanisms of action and effectiveness, and their potential for toxicity.
Collapse
Affiliation(s)
- Alamdar Hussain
- Department of Pharmaceutical Sciences, School of Pharmacy, University Health Sciences Center, 1300 Coulter Drive, Amarillo, TX 79106, USA
| | | | | | | |
Collapse
|
8
|
Montier T, Cavalier A, Delépine P, Guillaume C, Clément JC, Yaouanc JJ, Morel G, Thomas D, Férec C. The use of in situ hybridization to study the transgene pathway following cellular transfection with cationic phosphonolipids. Blood Cells Mol Dis 2003; 30:112-23. [PMID: 12667994 DOI: 10.1016/s1079-9796(03)00017-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Gene therapy is a promising field of research and biotechnological development. Considering their safety and non-immunogenicity, cationic lipids are widely used for gene transfer in vitro and show promise for in vivo gene transfer applications. However, a better understanding of the mechanisms by which transfection occurs and the limiting steps in cellular transfer of foreign DNA are critical for significant improvements of gene transfer. In this work, we have traced the plasmid DNA into human hematopoietic cell line (K562) using the in situ hybridization method in order to define the main difficulties in transfection and to design new agents better adapted to cellular constraints. In this hematopoietic cell line, after showing the efficiency of our synthetic vectors and optimizing their formulation, we observed that only 5 h after transfection the nucleus to cytoplasm signal ratio was three to one, whereas at 24 h it was one to one. In parallel, the level of the reporter protein strongly increased between these times. Those results emphasize the rapidity of transfection and lead one to imagine chemical modifications adjusted to the environment.
Collapse
Affiliation(s)
- Tristan Montier
- Equipe Mixte INSERM-Université Bretagne Occidentale 01-15, Institut des Sciences et Synergies de la Santé, University Teaching Hospital, EFS-Région Bretagne rue Félix Le Dantec, BP 454, 29275 Brest cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Zelphati O, Wang Y, Kitada S, Reed JC, Felgner PL, Corbeil J. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 2001; 276:35103-10. [PMID: 11447231 DOI: 10.1074/jbc.m104920200] [Citation(s) in RCA: 176] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
There are many very effective methods to introduce transcriptionally active DNA into viable cells but approaches to deliver functional proteins are limited. We have developed a lipid-mediated delivery system that can deliver functional proteins or other bioactive molecules into living cells. This delivery system is composed of a new trifluoroacetylated lipopolyamine (TFA-DODAPL) and dioleoyl phosphatidylethanolamine (DOPE). This cationic formulation successfully delivered antibodies, dextran sulfates, phycobiliproteins, albumin, and enzymes (beta-galactosidase and proteases) into the cytoplasm of numerous adherent and suspension cells. Two systems were used to demonstrate that the proteins were delivered in a functionally active form. First, intracellular beta-galactosidase activity was clearly demonstrated within X-gal-stained cells after TFA-DODAPL:DOPE-mediated delivery of the enzyme. Second, the delivery system mediated delivery of several caspases (caspase 3, caspase 8, and granzyme B) into cultured cell lines and primary cells triggering apoptosis. Mechanistic studies showed that up to 100% of the protein mixed with the lipid formulation was captured into a lipid-protein complex, and up to 50% of the input protein associated with cells. This lipid-mediated transport system makes protein delivery into cultured cells as convenient, effective, and reliable as DNA transfection.
Collapse
Affiliation(s)
- O Zelphati
- Gene Therapy Systems Inc., San Diego, California 92121, USA.
| | | | | | | | | | | |
Collapse
|